Literature DB >> 23957462

Diagnostic accuracy of faecal immunochemical test for screening individuals with a family history of colorectal cancer.

S C Ng1, J Y L Ching, V Chan, M C S Wong, B Y Suen, H W Hirai, T Y T Lam, J Y W Lau, S S M Ng, J C Y Wu, F K L Chan, J J Y Sung.   

Abstract

BACKGROUND: The role of a faecal immunochemical test (FIT) in screening individuals with a positive family history of colorectal cancer (CRC) is not clear. AIM: To assess the diagnostic accuracy of FIT using colonoscopy findings as the gold standard in identifying colorectal neoplasms.
METHODS: We analysed data from 4539 asymptomatic subjects aged 50-70 years who had both colonoscopy and FIT (Hemosure; W.H.P.M., Inc, El Monte, CA, USA) at our bowel cancer screening centre between 2008 and 2012. A total of 572 subjects (12.6%) had a family history of CRC. Our primary outcome was the sensitivity of FIT in detecting advanced neoplasms and cancers in subjects with a family history of CRC. A family history of CRC was defined as any first-degree relative with a history of CRC.
RESULTS: Among 572 subjects with a family history of CRC, adenoma, advanced neoplasm and cancer were found at screening colonoscopy in 29.4%, 6.5% and 0.7% individuals, respectively. The sensitivity of FIT in detecting adenoma, advanced neoplasm and cancer was 9.5% [95% confidence interval (CI), 5.7-15.3], 35.1% (95% CI, 20.7-52.6) and 25.0% (95% CI, 1.3-78.1), respectively. Among FIT-negative subjects who have a family history of CRC, adenoma was found in 152 (29.6%), advanced neoplasm in 24 (4.7%) and cancer in 3 (0.6%) individuals.
CONCLUSION: Compared with colonoscopy, FIT is more likely to miss advanced neoplasms or cancers in individuals with a family history of CRC.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 23957462     DOI: 10.1111/apt.12446

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  18 in total

1.  Diagnostic Accuracy of Fecal Immunochemical Test in Patients at Increased Risk for Colorectal Cancer: A Meta-analysis.

Authors:  Anastasia Katsoula; Paschalis Paschos; Anna-Bettina Haidich; Apostolos Tsapas; Olga Giouleme
Journal:  JAMA Intern Med       Date:  2017-08-01       Impact factor: 21.873

2.  Sex is a stronger predictor of colorectal adenoma and advanced adenoma than fecal occult blood test.

Authors:  Monika Ferlitsch; Georg Heinze; Petra Salzl; Martha Britto-Arias; Elisabeth Waldmann; Karoline Reinhart; Christina Bannert; Elisabeth Fasching; Peter Knoflach; Werner Weiss; Michael Trauner; Arnulf Ferlitsch
Journal:  Med Oncol       Date:  2014-08-14       Impact factor: 3.064

3.  Diagnostic accuracy of fecal immunochemical test in average- and familial-risk colorectal cancer screening.

Authors:  Joaquín Cubiella; Inés Castro; Vicent Hernandez; Carmen González-Mao; Concepción Rivera; Felipe Iglesias; María Teresa Alves; Lucía Cid; Santiago Soto; Luisa De-Castro; Pablo Vega; Jose Antonio Hermo; Ramiro Macenlle; Alfonso Martínez; Pamela Estevez; Estela Cid; Marta Herreros-Villanueva; Isabel Portillo; Luis Bujanda; Javier Fernández-Seara
Journal:  United European Gastroenterol J       Date:  2014-12       Impact factor: 4.623

4.  Participant-Related Risk Factors for False-Positive and False-Negative Fecal Immunochemical Tests in Colorectal Cancer Screening: Systematic Review and Meta-Analysis.

Authors:  Clasine M de Klerk; Lisanne M Vendrig; Patrick M Bossuyt; Evelien Dekker
Journal:  Am J Gastroenterol       Date:  2018-08-29       Impact factor: 10.864

5.  Identification of Hub Genes for Early Diagnosis and Predicting Prognosis in Colon Adenocarcinoma.

Authors:  Shuo Xu; Dingsheng Liu; Mingming Cui; Yao Zhang; Yu Zhang; Shiqi Guo; Hong Zhang
Journal:  Biomed Res Int       Date:  2022-06-21       Impact factor: 3.246

6.  Comparative effectiveness of five fecal immunochemical tests using colonoscopy as the gold standard: study protocol.

Authors:  Barcey T Levy; Jeanette M Daly; Yinghui Xu; Seth D Crockett; Richard M Hoffman; Jeffrey D Dawson; Kim Parang; Navkiran K Shokar; Daniel S Reuland; Marc J Zuckerman; Avraham Levin
Journal:  Contemp Clin Trials       Date:  2021-05-08       Impact factor: 2.261

7.  Regret on choice of colorectal cancer screening modality was associated with poorer screening compliance: a 4-year prospective cohort study.

Authors:  Martin C S Wong; Jessica Y L Ching; Victor C W Chan; Renee Bruggemann; Thomas Y T Lam; Arthur K C Luk; Justin C Y Wu; Francis K L Chan; Joseph J Y Sung
Journal:  PLoS One       Date:  2015-04-14       Impact factor: 3.240

8.  Serum sCD26 for colorectal cancer screening in family-risk individuals: comparison with faecal immunochemical test.

Authors:  O Otero-Estévez; L De Chiara; F J Rodríguez-Berrocal; M Páez de la Cadena; J Cubiella; I Castro; C Gonzalez-Mao; V Hernandez; V S Martínez-Zorzano
Journal:  Br J Cancer       Date:  2014-12-02       Impact factor: 7.640

9.  Should prior FIT results be incorporated as an additional variable to estimate risk of colorectal neoplasia? A prospective study of 5,813 screening colonoscopies.

Authors:  Martin C S Wong; Jessica Y L Ching; Victor C W Chan; Jeffrey P Shum; Thomas Y T Lam; Arthur K C Luk; Joseph J Y Sung
Journal:  PLoS One       Date:  2014-12-05       Impact factor: 3.240

10.  Evaluation of serum nucleoside diphosphate kinase A for the detection of colorectal cancer.

Authors:  Olalla Otero-Estévez; Loretta De Chiara; Leticia Barcia-Castro; María Páez de la Cadena; Francisco Javier Rodríguez-Berrocal; Joaquín Cubiella; Vicent Hernández; Vicenta Soledad Martínez-Zorzano
Journal:  Sci Rep       Date:  2016-05-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.